Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Hemoglobinopathies Market

Hemoglobinopathies Market Trends

Report ID: GMI11866
Published Date: Oct 2024
Report Format: PDF

Download Free Sample

Hemoglobinopathies Market Trends

Advancements in diagnostic technologies are driving progression in the industry, which focuses on blood disorders such as sickle cell disease and thalassemia. New methods, including next-generation sequencing (NGS), point-of-care testing, and high-throughput screening, enable quicker and more accurate detection of hemoglobinopathies at earlier stages. These innovations reduce diagnostic errors and allow for more personalized treatments. Additionally, improved accessibility and lower costs of genetic testing are increasing screening rates, particularly in high-risk populations. The demand for non-invasive diagnostic tools is also rising. These technological advancements are crucial in addressing the global burden of hemoglobin disorders, especially in regions with higher prevalence rates.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global hemoglobinopathies industry was valued at USD 6.3 billion in 2023 and is projected to grow at a 10.4% CAGR from 2024 to 2032, driven by the rising global prevalence of hemoglobin-related disorders.

The sickle cell disease segment dominated the market with USD 3.3 billion in 2023, supported by therapies such as blood transfusions, pain management drugs, and emerging treatments like gene therapy.

The North American hemoglobinopathies industry is expected to grow at a 10% CAGR, reaching USD 5.7 billion by 2032, driven by increased awareness, early diagnosis, and advanced treatment options.

Key players in the hemoglobinopathies industry include bluebird bio, Bristol-Myers Squibb Company, CHIESI FARMACEUTICI, Emmaus Medical, Medunik USA, Novartis, Pfizer, and Prolong Pharmaceuticals.